Description
The goal of the Agreement is to allow for critical review, theoretical and applied statistical feedback on modeling, results interpretation, help on drafting final reports and discuss the existing approaches for prognostic and predictive modeling building and validation under the framework of individual patients’ data meta-analysis (i.e. complex evidence synthesis) both for RCTs and non-randomized studies.This work is designed to help the Biogen Real World Evidence Biostats team in improving:
1. The use of Biogen phase 3 clinical trials Integrated Database (IBD) as a fundamental source for evidence to understand Biogen’s product from a portfolio perspective, as this data repository clearly represents an individual patients’ data network geometry.
2. The assessment of how Biogen MS products efficacy proven in phase 3 trials translates into effectiveness in the real practice. That is, the understanding of treatment efficacy-effectiveness gap to evaluate the potential benefits of Biogen products in populations not included in the RCTs and as well as to have the necessary understanding for planning future RCTs.
3. The use of evidence synthesis for the two separate frameworks of prognostic models and predictive models, focusing on the concepts of model building, model validation and transportability to other settings and/or populations.
| Period | Mar 2018 → … |
|---|---|
| Degree of Recognition | International |